Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trialGıancarlo Comı, Massimo Filippi, Lucia Moiola et al.|The Lancet|2009Cited by 587
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon betaDaniel Wynn, John Rose, Gilmore O’Neill et al.|The Lancet Neurology|2010Cited by 300
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trialDaniel S. Reich, Sibyl Wray, Sergii Moskovko et al.|The Lancet Neurology|2021Cited by 192
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndromeGiancarlo Comi, Massimo Filippi, Lucia Moiola et al.|Multiple Sclerosis Journal|2012Cited by 93